Published in Urology on April 15, 2010
Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology (2014) 2.62
Serum methionine metabolites are risk factors for metastatic prostate cancer progression. PLoS One (2011) 1.03
Management of low (favourable)-risk prostate cancer. BJU Int (2011) 0.84
Retracted Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance. BJU Int (2013) 0.82
Current status of active surveillance in prostate cancer. Investig Clin Urol (2016) 0.81
Prostate cancer in men of African origin. Nat Rev Urol (2015) 0.81
Localization of higher grade tumor foci in potential candidates for active surveillance who opt for radical prostatectomy. Prostate Int (2013) 0.79
The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer. BMC Cancer (2016) 0.77
Oncologic outcomes following radical prostatectomy in the active surveillance era. Can Urol Assoc J (2013) 0.77
A critical review of the epidemiology of Agent Orange/TCDD and prostate cancer. Eur J Epidemiol (2014) 0.77
Predictive factors of unfavorable prostate cancer in patients who underwent prostatectomy but eligible for active surveillance. Prostate Int (2014) 0.76
Editorial comment. Urology (2010) 0.75
Pathologic Outcomes in Men with Low-risk Prostate Cancer Who Are Potential Candidates for Contemporary, Active Surveillance Protocols. J Korean Med Sci (2015) 0.75
Editorial comment. Urology (2010) 0.75
Obesity and Prostate Cancer: A Focused Update on Active Surveillance, Race, and Molecular Subtyping. Eur Urol (2016) 0.75
Is active surveillance a suitable option for African American men with prostate cancer? A systemic literature review. Prostate Cancer Prostatic Dis (2017) 0.75
Increasing low risk prostate cancer incidence in United States Air Force servicemen and selection of treatments. J Urol (2011) 0.75
Tumor volume improves the long-term prediction of biochemical recurrence-free survival after radical prostatectomy for localized prostate cancer with positive surgical margins. World J Urol (2016) 0.75
Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 14.35
20-year outcomes following conservative management of clinically localized prostate cancer. JAMA (2005) 12.25
Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA (1994) 9.15
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 8.72
Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer (2008) 4.77
The changing face of prostate cancer. J Clin Oncol (2005) 3.84
Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol (2003) 3.62
Active surveillance for early-stage prostate cancer: review of the current literature. Cancer (2008) 3.18
Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol (2007) 3.14
Agent Orange exposure, Vietnam War veterans, and the risk of prostate cancer. Cancer (2008) 2.49
Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol (2009) 2.39
Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol (2008) 2.22
PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol (2008) 2.00
Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology (2002) 1.81
Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications. Urology (2007) 1.67
Do younger men have better biochemical outcomes after radical prostatectomy? Urology (2004) 1.24
Small transrectal ultrasound volume predicts clinically significant Gleason score upgrading after radical prostatectomy: results from the SEARCH database. J Urol (2008) 1.21
Active surveillance for favorable risk prostate cancer: rationale, risks, and results. Urol Oncol (2007) 1.10
Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE. J Urol (2003) 1.09
Patient risk stratification using Gleason score concordance and upgrading among men with prostate biopsy Gleason score 6 or 7. Urol Oncol (2008) 1.09
Does initial surveillance in early prostate cancer reduce the chance of cure by radical prostatectomy?--A case control study. Scand J Urol Nephrol (2003) 1.07
A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes? J Urol (2008) 1.04
Stage migration and grade inflation in prostate cancer: Will Rogers meets Garrison Keillor. J Natl Cancer Inst (2005) 1.02
Active surveillance for good risk prostate cancer: rationale, method, and results. Can J Urol (2005) 1.00
Staging saturation biopsy in patients with prostate cancer on active surveillance protocol. Urology (2008) 0.95
Radical prostatectomy for low risk carcinoma of the prostate. World J Urol (2008) 0.85
Exposure to Agent Orange is a significant predictor of prostate-specific antigen (PSA)-based recurrence and a rapid PSA doubling time after radical prostatectomy. BJU Int (2009) 0.83
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Autonomic nerve development contributes to prostate cancer progression. Science (2013) 6.11
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst (2009) 4.87
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol (2003) 3.62
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25
The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials (2008) 3.25
Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys (2008) 3.22
Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. J Clin Oncol (2010) 3.13
A framework for the identification of men at increased risk for prostate cancer. J Urol (2009) 3.07
Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol (2005) 2.57
Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys (2011) 2.57
The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst (2008) 2.46
Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol (2013) 2.46
Prostate cancer severity among low income, uninsured men. J Urol (2008) 2.38
Castration-resistant prostate cancer: AUA Guideline. J Urol (2013) 2.36
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol (2006) 2.31
The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29
Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev (2006) 2.28
Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database. J Urol (2009) 2.23
Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database. Urology (2009) 2.23
Prostate cancer in men using testosterone supplementation. J Urol (2005) 2.12
Association between exercise and primary incidence of prostate cancer: does race matter? Cancer (2013) 2.07
High-risk prostate cancer: from definition to contemporary management. Eur Urol (2012) 2.06
Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06
Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol (2012) 2.05
Length of site-specific positive surgical margins as a risk factor for biochemical recurrence following radical prostatectomy. Int J Urol (2011) 2.04
Obesity and prostate cancer: weighing the evidence. Eur Urol (2012) 2.01
Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer (2006) 1.97
The role of primary androgen deprivation therapy in localized prostate cancer. Eur Urol (2009) 1.97
Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. Cancer (2007) 1.96
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
Growth inhibitory effect of low fat diet on prostate cancer cells: results of a prospective, randomized dietary intervention trial in men with prostate cancer. J Urol (2010) 1.94
The role of genetic markers in the management of prostate cancer. Eur Urol (2012) 1.88
Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients. Int J Radiat Oncol Biol Phys (2004) 1.86
Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology (2003) 1.84
The correlation between metabolic syndrome and prostatic diseases. Eur Urol (2011) 1.83
Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. Eur Urol (2012) 1.81
Intensive lifestyle changes may affect the progression of prostate cancer. J Urol (2005) 1.81
Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology (2002) 1.81
Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database. Prostate (2012) 1.76
Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol (2009) 1.75
Differing perceptions of quality of life in patients with prostate cancer and their doctors. J Urol (2009) 1.72
Structural heterogeneity and protein composition of exosome-like vesicles (prostasomes) in human semen. Prostate (2009) 1.68
Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications. Urology (2007) 1.67
Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. Cancer (2013) 1.66
Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer. J Urol (2004) 1.66
The relationship between nutrition and prostate cancer: is more always better? Eur Urol (2012) 1.66
Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol (2012) 1.64
Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study. Cancer Epidemiol Biomarkers Prev (2012) 1.63
Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol (2007) 1.63